Stevanato Group (NYSE:STVN) Raised to “Strong-Buy” at TD Cowen

Stevanato Group (NYSE:STVN) was upgraded by equities research analysts at TD Cowen to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities analysts have also recently commented on STVN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Stevanato Group in a report on Monday, June 8th. KeyCorp lowered their price objective on shares of Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Citigroup dropped their price objective on shares of Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Morgan Stanley reduced their target price on shares of Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. Finally, Wolfe Research assumed coverage on shares of Stevanato Group in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Stevanato Group has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Up 0.5%

Stevanato Group stock opened at €17.63 on Wednesday. Stevanato Group has a fifty-two week low of €12.89 and a fifty-two week high of €28.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The company has a market capitalization of $5.34 billion, a P/E ratio of 29.88, a PEG ratio of 1.57 and a beta of 0.78. The stock has a 50-day simple moving average of €17.06 and a 200-day simple moving average of €17.44.

Stevanato Group (NYSE:STVN) last announced its earnings results on Friday, May 8th. The company reported €0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.12 by (€0.01). The firm had revenue of €273.57 million during the quarter. Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. Equities research analysts expect that Stevanato Group will post 0.68 earnings per share for the current year.

Hedge Funds Weigh In On Stevanato Group

Institutional investors have recently bought and sold shares of the company. ArrowMark Colorado Holdings LLC lifted its holdings in shares of Stevanato Group by 6.7% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,392,581 shares of the company’s stock valued at $35,859,000 after buying an additional 86,971 shares during the period. Cooper Investors PTY Ltd. grew its holdings in Stevanato Group by 17.8% during the fourth quarter. Cooper Investors PTY Ltd. now owns 695,245 shares of the company’s stock worth $13,988,000 after acquiring an additional 104,937 shares during the period. Bamco Inc. NY raised its position in Stevanato Group by 4.5% in the third quarter. Bamco Inc. NY now owns 1,973,759 shares of the company’s stock worth $50,824,000 after acquiring an additional 85,709 shares in the last quarter. Jennison Associates LLC lifted its holdings in Stevanato Group by 13.7% in the fourth quarter. Jennison Associates LLC now owns 1,772,896 shares of the company’s stock valued at $35,671,000 after acquiring an additional 213,602 shares during the period. Finally, Rhenman & Partners Asset Management AB purchased a new stake in shares of Stevanato Group during the 3rd quarter worth $1,313,000.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.